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AbstrACt
Introduction BCG vaccination reduces all- cause infant 
mortality in high- mortality settings by more than can 
be attributed to protection against tuberculosis. This is 
proposed to result from non- specific protection against 
non- vaccine targeted (‘off- target’) infections. There is also 
evidence that BCG protects against allergic diseases.
Methods and analysis The Melbourne Infant Study: 
BCG for Allergy and Infection Reduction is a phase III 
multicentre, single- blinded, randomised controlled trial. 
A total of 1438 healthy neonates will be randomised to 
receive either BCG vaccination or no BCG vaccination 
in the first 10 days of life. Measures of allergy, eczema, 
infection and asthma will be obtained from parent- 
completed questionnaires 3 monthly in the first year and 6 
monthly from 1 to 5 years of age, and clinical assessments 
at 1 and 5 years of age. Biological samples will also be 
collected for future immunological studies.
Analysis primary outcome The proportion of 
participants with measures of allergy and infection (atopic 
sensitisation, eczema, lower respiratory tract infection) 
at 1 and 5 years of age, and asthma at 5 years of age. 
Secondary outcomes: (1) the proportion of participants 
with additional measures of allergy, eczema, asthma and 
infections; (2) medication use for eczema and asthma; (3) 
the severity and age of onset of eczema and asthma; (4) 
the number of episodes of infection; (5) hospitalisations 
for infections and (6) laboratory measures of immune 
responses.
Ethics and dissemination This trial has ethical and 
governance approval from Mercy Health Human Research 
Ethics Committee (HREC, No. R12-28) and Royal Children’s 
Hospital HREC (No. 33025) with additional governance 
approval from Barwon Health and St John of God, Geelong, 
Victoria. Results of this trial will be published in peer- 
reviewed journals and presented at scientific conferences.
trial registration number NCT01906853
IntroduCtIon
The BCG vaccine is given to more than 
85% of infants worldwide to protect against 
tuberculosis (TB).1 In addition to protecting 
against TB, vaccination with BCG- Denmark 
reduces all- cause neonatal mortality in a 
high- mortality setting,2–4 likely by protecting 
against non- mycobacterial infections.4 5
Observational studies suggest that the bene-
ficial ‘non- specific’ (heterologous) effects of 
BCG on the developing immune system may 
also reduce the prevalence of allergic disease 
and asthma in children.6 However, meta- 
analyses of observational studies have had 
inconsistent findings.7–9 The two randomised 
controlled trials (RCTs) that have investigated 
the effect of BCG on infant allergic disease 
both found that BCG vaccination reduced 
infant eczema (medication for eczema at 18 
strengths and limitations of this study
 ► The use of well- defined, internationally accepted 
outcome measures in a large- scale randomised trial.
 ► Low tuberculosis burden in Australia reduces po-
tential influence of Mycobacterium tuberculosis 
exposure.
 ► Use of oral food challenge in addition to skin prick 
testing provides a robust and clinically relevant 
measure of food allergy.
 ► Inability to blind parents to infants’ randomisation 
group due to the scar resulting from BCG vaccination.
 ► Routine scheduled non- live vaccines administered 
subsequent to randomisation might attenuate the 
beneficial non- specific effects of BCG.
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months of age10; clinically diagnosed eczema at 13 months 
of age11) but did not have a statistically significant effect on 
the prevalence of allergic sensitisation or food allergy at 
13 or 18 months of age. However, in these studies, allergic 
outcomes were determined by parent questionnaire and 
serum IgE, rather than clinical assessment. Studies assessing 
the impact of BCG vaccination on asthma have had more 
consistent findings with two meta- analyses concluding the 
BCG reduces the risk of asthma by 14%–27%.7 9
As a result of a reduction in the prevalence of TB in several 
high- income and middle- income countries, BCG has been 
removed from routine vaccination schedules. This might 
have contributed to the increased prevalence of allergic 
diseases over the past three decades.12–16 It is proposed 
that, by acting as an early life microbial stimulus,17 BCG 
prevents allergy by skewing the developing immune system 
in predisposed individuals away from the T helper (Th) 2 
type immune response typically associated with allergy.6 8
BCG vaccination induces potent Th1 responses in 
neonates. In adults, it induces trained immunity in innate 
immune cells18 19 and promotes Th1 and Th17 responses 
to non- mycobacterial pathogens.20–22
Two large observational studies provide further 
evidence that BCG vaccination protects against non- 
mycobacterial infections, particularly sepsis and respira-
tory infections.23 24 However, BCG- mediated protection 
against these non- vaccine targeted or ‘off- target’ infec-
tions might be limited by subsequent vaccination with 
non- live vaccines which are proposed to counteract the 
beneficial non- specific effects of BCG.4 25 26 Studies in a 
low- mortality setting, including a recent RCT of neonatal 
BCG vaccination27 and an observational study of over 
19 000 infants,28 support this hypothesis with protective 
effects of BCG against off- target infections most evident in 
early infancy, before administration of non- live vaccines.29 
Moreover, in the RCT, the protective effect of BCG was 
only evident in infants of BCG- vaccinated mothers.27
Subsequent to a 2004 WHO recommendation, an 
increasing number of countries have implemented routine 
neonatal hepatitis B vaccination.30 Therefore, the potential 
impact of this vaccine on the beneficial non- specific effects 
of neonatal BCG vaccination also requires consideration.
Australia, where routine BCG vaccination was halted in 
the 1980s—has one of the highest rates of infant allergic 
disease globally.31–33 It, therefore, represents an ideal 
setting in which to assess the impact of BCG on allergic 
disease. The Melbourne Infant Study: BCG for Allergy 
and Infection Reduction (MIS BAIR) is an RCT to investi-
gate whether neonatal BCG vaccination reduces the prev-
alence of allergic and infectious disease.
study AIMs
Primary aims
To determine whether neonatal BCG vaccination 
compared with no BCG vaccination, reduces allergic 
disease, infection and asthma in infants and children in 
Australia.
secondary aims
To evaluate the immunological mechanisms under-
lying the non- specific effects of BCG by comparing the 
immune responses in BCG vaccinated to those in BCG- 
naïve infants.
MEthods And AnAlysIs
study design and setting
This is a phase III multicentre, single- blinded, RCT of 
neonatal BCG vaccination compared with no BCG vacci-
nation. Recruitment commenced in August 2013 and 
study follow- up will be completed by 2022.
The study population will be healthy neonates 0–10 days 
of age born at one of the study site hospitals in Victoria, 
Australia. Recent studies of the burden of allergic diseases 
in this population have reported high a prevalence of 
eczema (28%34) allergic sensitisation (18%) and clinically 
significant food allergy (10.4%35) at 12 months of age, as 
well as high rates (22%) of asthma by 4–5 years.36
Study sites comprise: the Murdoch Children’s Research 
Institute (MCRI), Melbourne; Royal Children’s Hospital 
(RCH) Melbourne; Mercy Hospital for Women, Heidel-
berg; Werribee Mercy Hospital, Werribee; University 
Hospital Geelong, Geelong; and St John of God Geelong 
Hospital, Geelong.
Patient and public involvement
Patients and public were not involved in the design of 
this study. The results of this study will be disseminated to 
study participants via participant newsletter.
Eligibility criteria
The inclusion criteria comprise: healthy neonates up to 
10 days of age; birth weight greater than 1500 g; gesta-
tional age equal to or greater than 32 weeks, mothers 
testing HIV negative during pregnancy, English- speaking 
mother and parent/legal guardian able to complete ques-
tionnaires in English and attend study visit. The exclusion 
criteria comprise: any indication for BCG vaccination in 
the first year of life as per the Australian national guide-
lines37; known or suspected HIV infection; infant at risk of 
immunodeficiency; serious underlying illness (including 
fever) or medical instability; skin infection or other skin 
condition; need for treatment with hepatitis B immuno-
globulin; multiple birth of more than twins; older sibling 
in the study.
Intervention
Infants will be randomised to receive BCG vaccination 
or no BCG vaccination in the first 10 days of life. Infants 
randomised to the BCG vaccination group will be admin-
istered a single intradermal injection of 0.05 mL Mycobac-
terium bovis BCG vaccine, Danish Strain 1331 (1–4×105 
colony forming units) over the left deltoid within 24 hours 
of randomisation.
reasons for withdrawal
Reasons for withdrawal from the study will be recorded 
along with demographic data. These may include: 
3Messina NL, et al. BMJ Open 2019;9:e032844. doi:10.1136/bmjopen-2019-032844
Open access
Table 1 Data and sample collection schedule
Infant age Antenatal 0–10 d 3 m 6 m 9 m 1 y 1.5 y 2 y 2.5 y 3 y 3.5 y 4 y 4.5 y 5 y
Recruitment and randomisation
  Eligibility check and consent ✓ ✓
  Baseline questionnaire ✓ ✓
  Birth questionnaire ✓
  Randomisation±vaccination ✓
  Full blood examination ✓*
Post randomisation
  Perinatal hospital data ✓
  Parent questionnaire ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
  Clinical eczema assessment ✓ ✓
  Skin prick test ✓ ✓
  Oral food challenge ✓† ✓†
  Biological sample collection ✓‡ ✓§ ✓ ✓
*Soon after birth.
†If indicated by skin prick test result.
‡7±4 days postrandomisation.
§5–8 months of age.
d, days; m, months; y, year.
Table 2 Baseline questionnaire data
Family and demographic Family history of allergic disease (allergy, eczema, hay fever, asthma), maternal BCG 
vaccination, parent education, parent country of birth, ethnicity.
Household environment Size, composition, smoking, pets, region (postal code).
Maternal prenatal Age, weight, height, prior pregnancies, vaccinations, smoking, antibiotics, vitamin D, probiotics 
other medications or supplements.
Birth Mode of delivery*, birth site*, plurality*, birth complications, gestational age, weight, sex, 
antibiotics or other medications during labour.
*Required for stratification prior to randomisation.
protocol violations, indication for participant to receive 
BCG vaccine within the first year of life37, serious adverse 
event (SAE) or other AE or guardian/parent request.
data and sample collection
Timing of data and sample collection in MIS BAIR is 
summarised in table 1. Web- based questionnaires will 
be administered to parents at the time of recruitment, 
randomisation and when the participant is 3, 6, 9 and 12 
months of age as well as 6 monthly up to 5 years of age 
using the Research Electronic Data Capture (REDCap) 
platform.38 Infant perinatal data, including infections, 
medications and hospital admission, will be obtained 
from the birth site records. Participants will be invited 
to optional study visits for biological sample collection 7 
days (±4 days) after randomisation and at 6 months (5–8 
months) of age. Infants will be invited for clinical assess-
ment and biological sample collection at 1 year (between 
11 and 24 months) and 5 years (between 5 and 6 years) 
of age.
Parent questionnaires
To collect data on potential confounding factors and 
for stratification prior to randomisation, baseline parent 
questionnaires will be used to collect data on demo-
graphic, environmental, prenatal and birth factors 
(table 2). When the participants are 3, 6, 9 and 12 months 
of age, questionnaires will be provided to parents to 
collect data on diet, medications and potential environ-
mental confounders, and to collect data for primary and 
secondary outcomes (table 3).
Clinical assessments
Allergic sensitisation: skin prick testing (SPT) to the 
following panel of allergens will be assessed: food aller-
gens—cow’s milk, raw egg, peanut, sesame, cashew, 
hazelnut, shellfish, walnut (at 5- year visit only); other aller-
gens—Dermatophagoides pteronyssinus 1 (house dust mite), 
cat, dog, Alternaria tenuis (mould) and rye grass pollen. 
SPT will be done according to standard guidelines.39 For 
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Table 3 Three and six monthly questionnaire outcome data
Illnesses Any episode of illness, infant age, duration of illness, symptoms, medial consultations and hospital admissions, 
diagnosis and any treatments/medications.
Eczema Symptoms of eczema, infant age at onset of eczema, distribution of eczema, use of eczema medications, medical 
consultations and hospital admissions. Includes modified U.K. working party’s diagnostic criteria for atopic 
dermatitis and modified patient- oriented eczema measure (POEM) tool questions.52 53
Allergies Any episodes of food or other allergies, infant age, allergen, symptoms, severity, diagnosis and any treatment.
Asthma International Study of Asthma and Allergies in Childhood (ISAAC) questions,54 55 asthma medication usage, 
symptom severity, acute exacerbations and healthcare utilisation, including hospitalisations.
Diet Breast milk feeding, formula milk feeding, food introduction, dietary supplements.
Other Household composition, childcare, pets and other animals, household smoking, drinking water source, 
vaccinations, other medications or supplements, other diseases/disabilities, BCG complications, overseas travel, 
non- illness associated hospital admissions.
each food allergen tested, data will also be collected on 
prior ingestion, exposure, reactions and tolerance (after 
the SPT weal size is assessed).
Eczema: Severity of eczema will be assessed using 
Scoring of Atopic Dermatitis (SCORAD).40
Oral food challenge (OFC): Participants with a weal 
diameter ≥1 mm greater than the negative control to 
selected food allergens during SPT will be invited to 
have an OFC as detailed in online supplementary figure 
1. OFCs will be done at MCRI according to Australasian 
Society of Clinical Immunology and Allergy guidelines 
as used by the RCH Allergy Clinic and the HealthNuts 
study.41 The different pathways that will occur during an 
OFC detailed in online supplementary figure 2.
Other: Weight, height, skin, eye and hair colour, BCG 
vaccination site including scar measurement and photo-
graph. BCG vaccination site assessment will occur after all 
other assessments are complete.
biological sample collection
Full blood examination: A capillary blood sample will be 
collected from participants soon after birth as a prelimi-
nary screen for primary T- cell immunodeficiencies. This 
may be done before or after randomisation.
Peripheral blood: Peripheral blood samples will be 
collected at 7 days, 7 months, 1 year and 5 years of age. 
These samples will be used for immediate immune stim-
ulation experiments as well as separation and storage of 
peripheral blood mononuclear cells and granulocytes, 
plasma and plasma- depleted cells at −80 °C or in liquid 
nitrogen, as appropriate. These samples will be retained 
for future immunological analysis.
Stool: From the day of birth, participant’s parents will 
be requested to collect a stool sample on each day (up 
to seven samples) and store it in a domestic freezer until 
collection at the 7- day postrandomisation study visit. Addi-
tional stool samples will be collected during the 7- month 
and 1- year study visits or by parents prior to the 1- year 
study visit using an in- home stool collection kit provided 
by the study team.
outcomes
Primary outcomes
The primary outcomes are the proportions of infants with 
the following measures of allergic disease and infection at 
1 year and 5 years of age:
 ► Atopic sensitisation (positive SPT) to one or more of 
a panel of food and aeroallergens.
 ► Eczema (based on Williams’ UK diagnostic criteria).
 ► Lower respiratory tract infection (LRTI) episode ever 
(1 year) or hospitalisation ever (5 years).
 ► Asthma (ISAAC definition) ever and current (5 years 
of age only).
Secondary outcomes
The secondary outcomes are the following additional 
measures of allergy and infection:
Allergy
The proportion of infants with clinical food allergy 
(online supplementary figures 1 and 2); atopic sensiti-
sation with ≥3 mm weal diameter to any allergen; atopic 
sensitisation to multiple allergens; parent report of food 
allergy to any food; atopic sensitisation to egg allergen; 
clinical egg allergy; atopic wheeze.
Eczema
Severity of eczema; age of onset of eczema and propor-
tions of clinically diagnosed eczema and steroid use for 
eczema.
Infections
Proportion of infants with or rate of the following: any 
infection; upper respiratory tract infection; LRTI; diar-
rhoea with vomiting; rash with fever; fever; hospitalisation 
for infection; hospitalisation for respiratory tract infection.
Asthma
The proportion of infants with current asthma, asthma 
severity and medication use for asthma.
sample size and power calculation
This study aims to randomise a total of 1438 partici-
pants. This sample size is calculated based on an assumed 
5Messina NL, et al. BMJ Open 2019;9:e032844. doi:10.1136/bmjopen-2019-032844
Open access
minimum 80% retention rate, resulting in an expected 
minimum 1150 infants with 1- year data available. With a 
final sample size of 575 in each arm, this study is powered 
to detect a minimum 35% reduction in atopic sensitisa-
tion, 25% reduction in eczema and 25% reduction in 
LRTI with a power of 80% in the first year of life and a 
minimum 37% reduction in atopic sensitisation, 26% 
reduction in eczema, 26% reduction in LRTI and 27% 
reduction in asthma with a power of 80% at 5 years of age. 
These differences are based on the previously reported 
prevalence of atopic sensitisation, eczema, LRTI and 
asthma in Australian infants at 1 and 5 years of age.35 36 42
recruitment
Recruitment will occur in two stages: (1) early consent 
will be sought from pregnant women attending antenatal 
clinics or in the postnatal ward at a study site; (2) addi-
tional pregnant women or mothers interested in partici-
pating but not being cared for at a study site may also be 
recruited if they contact the research team antenatally or 
within 10 days of delivery. Consent to participate in the 
study will be verbally confirmed after the birth of antena-
tally recruited infants and prior to randomisation.
randomisation
Recruited neonates will only be randomised after confir-
mation that they still fulfil inclusion criteria and do not 
meet any exclusion criteria. Randomisation to BCG vacci-
nation or no BCG vaccination will be done in a 1:1 ratio 
using the REDCap randomisation function.38 The rando-
misation schedule will be established by a statistician 
external to the study using random permuted blocks with 
a minimum of three different block sizes. Randomisation 
will be stratified by: (1) site (hospital); (2) method of 
delivery (Caesarean vs non- Caesarean) and (3) plurality 
of birth (twins vs singletons). Twins will be assigned to the 
same intervention arm.
blinding
As BCG vaccination results in the formation of a scar at 
the vaccination site in 93%–99% of infants,43–46 blinding 
with the use of a placebo is not possible. For blinding 
of clinical assessments, prior to commencement of the 
1- year and 5- year study visits, each participant’s left upper 
arm will be covered with a bandage by the parent or a 
member of the study team not involved with the assess-
ment to hide the potential scar site. Clinical assessments 
will be done by a member of the study team or clinical 
staff member who was not involved in the randomisation 
of the participant.
statistical analysis
Statistical analysis of primary and secondary outcomes 
will be overseen by the trial statistician. Primary analysis 
will be by intention to treat, including all randomised 
participants where outcome data are available. Data will 
be collected according to Consolidated Standards of 
Reporting Trials guidelines for reporting randomised 
trials.47
outcomes
Primary outcomes
Comparison between BCG- vaccinated and BCG- naïve 
infants will be estimated using binary regression adjusted 
for the stratification factors used during randomisation. 
Results will be presented as risk difference with 95% CIs.
Secondary outcomes
Comparison between the BCG- vaccinated and BCG- naïve 
infants will be estimated using binary linear or Poisson 
regression adjusted for the stratification factors used 
during randomisation. Results will be presented as risk 
difference with 95% CI.
Missing data
If the proportion of missing data is less than 5%, the 
primary analysis will be a complete- case analysis. Other-
wise, the frequency and patterns of missing data will 
be examined and, if appropriate, multiple imputation 
models will be conducted for the outcome variables. Fifty 
completed data sets will be imputed by chained equa-
tions including all the children initially randomised. The 
primary outcome, strata variable (mode of birth: vaginal/
caesarean) and the variables predictive of missingness 
and allergy, eczema, infection or asthma will be included 
in the imputation model.
Subgroup analysis
Prior to any subgroup analysis, adjusted models including 
the stratification factors used in randomisation, the 
randomisation assignment and the subgroup variable as 
covariates will be used to estimate the interaction between 
the intervention and the subgroup variable. Where these 
models provide evidence that the intervention varies 
between subgroups, specific subgroup estimates and CIs 
will be presented obtained from the adjusted model. The 
subgroups are presence or absence of BCG scar; timing 
of BCG administration; maternal BCG vaccination; sex; 
mode of delivery; season of birth; timing of hepatitis B 
vaccination. For allergy, eczema and asthma outcomes, 
an additional subgroup variable, family history of allergic 
disease or asthma, will be assessed.
data monitoring and auditing
The independent data safety and monitoring committee 
(DSMC), consisting of an independent statistician, neona-
tologist and paediatric infectious diseases consultant, will 
meet to review data and participant safety 6 monthly.
risks
The potential risks of participation in this study may be 
related to: (1) adverse reactions to BCG vaccination: 
subcutaneous abscess, exaggerated local reaction, lymph-
adenitis, keloid scaring, osteitis and disseminated infec-
tion.48 In Australia, adverse reactions to BCG vaccine 
occur in 15.3 out of 10 000 doses49; (2) blood collection: 
discomfort, bruising and rarely minor infection or blood 
clots (3) clinical assessments of allergy: anaphylactic reac-
tions may occur during OFC, during SPT (rare) and as 
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a late reaction to OFC (from further allergen exposures 
during the subsequent week). The protocols and work-
flows for SPT and OFC mitigate the risk of anaphylactic 
reactions and their safety has been demonstrated in 
previous clinical trials (online supplementary figures 1 
and 2).41 All AE will be recorded, and SAEs reported to 
the study site Human Research Ethics Committee and the 
DSMC.
outlook and significance
The findings of MIS BAIR will provide evidence as to 
whether neonatal BCG vaccination, a low- cost, readily 
available intervention, reduces the prevalence of aller-
gies and infections in the first one and 5 years of life, and 
asthma in the first 5 years of life. An immune priming 
benefit of neonatal BCG against these diseases would 
have considerable public health implications and thus 
inform guidelines for BCG vaccine policies worldwide.
limitations
The potential limitations of MIS BAIR include the 
inability to blind the parent(s)/guardian(s) to the infant’s 
randomisation assignment. This may lead to bias or lower 
compliance if parent(s)/guardian(s) are disappointed 
with the randomisation assignment. However, blinding 
will be done for the 13- month study clinical assess-
ments from which several of the primary and secondary 
outcomes measures of allergy and eczema are obtained. 
We expect that there will be greater recruitment of partic-
ipants with a family history of allergic disease, which may 
limit the generalisability of our findings. We will, there-
fore, collect data in relation to family history to enable 
us to consider for this in later analyses. BCG was followed 
by multiple administrations of non- live vaccines, and this 
might attenuate the beneficial non- specific effects of 
BCG.50 51
EthICs And dIssEMInAtIon
A record of consents and refusals will be maintained 
on the study REDCap database. Parent(s)/guardian(s) 
of participants will be informed of their option to with-
draw from the study at any time. An electronic or hard 
copy parent/guardian information and consent form will 
be completed a parent/guardian as part of the consent 
process. Results of this trial will be published in peer- 
reviewed journals and presented at scientific conferences.
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